Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Oncology

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York. Kuan said the company believes the therapy cou

MarketBeat

CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies

CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration. John Hanna, chief executiv

MarketBeat

Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path

Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR mutations, Chief Executive Officer Mark Velleca said during a Jefferies fireside chat following the company

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m

MarketBeat

National Cancer Survivors Day Is Sunday — And for Dallas's Pancreatic Cancer Patients, There Has Never Been More Reason to Celebrate

National Cancer Survivors Day arrives with unprecedented hope for Dallas-Fort Worth pancreatic cancer patients as a breakthrough new drug nearly doubles survival in a landmark Phase 3 trial, marking a major advance against one of the deadliest cancers.

Medical Daily

Cancer breakthroughs: Does a string of advances signal turning point?

It’s not every day that a standing ovation at a medical conference goes viral. Dateline: Chicago, at the annual conference of the American Society of Clinical Oncology. Doctors from around the world rose to their feet to applaud the announcement of a new pill that doubles survival time for pancreatic…

France 24

Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference

Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company’s focus on off-the-shelf gamma delta 1 T-cell therapies for autoimmune

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

"Transformative Advance" in Cancer Treatment Emerges in Dallas — New Pill Shows Rare Survival Jump in Pancreatic Cancer Patients

Pancreatic Cancer treatment may be entering a new era as a breakthrough pill nearly doubles survival in metastatic patients, offering new hope for one of the deadliest forms of cancer.

Medical Daily

How a $150 million gift brought Texas Children’s and MD Anderson together for childhood cancer

A significant donation of $150 million from the Kinder Foundation is uniting Texas Children's Hospital and UT MD Anderson Cancer Center. This gift supports the new Kinder Children's Cancer Center. The initiative focuses on merging existing strengths in pediatric care and cancer research. The goal is to bridge the gap…

The Times of India

New Cancer Treatments Show Promise Against Some of the Deadliest Tumors, Researchers Report

The developments were highlighted during presentations at major oncology meetings and reported by The Guardian on June 1, as researchers unveiled data suggesting that several next-generation treatments may improve outcomes for patients who have exhausted standard options.

Medical Daily

ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs

ALX Oncology (NASDAQ:ALXO) executives said the company is focused on advancing two clinical-stage oncology programs, with upcoming data readouts expected to shape potential later-stage development plans for its lead CD47 program, evorpacept, and its EGFR-targeted antibody-drug conjugate, ALX2004. S

MarketBeat

Avammune’s big bet: Why the future of cancer treatment may come in a pill

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherapies designed for broader patient access.

The Economic Times

Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest

Three studies add to evidence that jabs could be part of cancer-fighting toolkit to cut risk of developing or dying from disease

The Guardian - UK

Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

Corbus Pharmaceuticals (NASDAQ:CRBP) executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company’s CRB-701 program on recurrent or metastatic oropharyngeal head and neck cancer, particularly in patients whose disease is associated with human p

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint

GRAIL (NASDAQ:GRAL) said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify more cancers through screening and reduce stage 4 diagnoses, though the company confirmed that a primary endpoint in its lar

The Independent UK

Doctors hail cancer injection that can destroy entire tumors

The results of the trial will be presented during the American Society of Clinical Oncology annual meeting in Chicago

The Guardian - UK

Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim

Results presented at oncology conference in Chicago show Galleri test failed to reduce late-stage cancer diagnoses

AAP

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

FLORENCE, Italy and NEW YORK, May 29, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present safety and preliminary efficacy for the…

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

Want to Stay Current on Latest in Cancer Prevention and Treatment? Free Service from NCCN Can Help

PLYMOUTH MEETING, Pa., May 27, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—the nonprofit alliance of leading cancer centers responsible for essential NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) that providers rely on worldwide—has launched a new, free service. Anyone is now able to sign up for weekly…

MarketBeat

MacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates

MacroGenics (NASDAQ:MGNX) Chief Executive Officer Eric Risser said the biotechnology company has strengthened its balance sheet through two recent transactions while preparing for a series of clinical updates across its oncology pipeline. Speaking during an informal discussion hosted by Stifel seni

MarketBeat

IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit

IDEAYA Biosciences (NASDAQ:IDYA) executives highlighted recent clinical progress across the company’s oncology pipeline during a fireside chat at TD Cowen’s seventh annual Oncology Innovation Summit, with the discussion focused primarily on darovasertib combinations in uveal melanoma and several ear

International Business Times

Manish Singh's View of Oncology Innovation Through Clinical Insight and Long-Term Thinking

Dr. Singh's professional journey spans scientific research, venture investing, and biotechnology leadership, experiences that collectively shaped his perspective on how meaningful innovation occurs.

AAP

DOSIsoft Launches DOSIsoft Theranostics, a Dedicated Entity to Accelerate Software Innovation for Personalized Nuclear Medicine and Theranostics

PARIS, May 26, 2026 /PRNewswire/ -- Ahead of SNMMI 2026, DOSIsoft, a leading provider of dosimetry software for radiation oncology and nuclear medicine, today announced the launch of DOSIsoft Theranostics, a dedicated entity focused on developing theranostics software for broader routine clinical adoption. As an independent player fully dedicated to…

The Mary Sue

Philadelphia Nurse spots her Jamaican Co-Worker’s Name on her Hospital’s Memorial Paper for Patients Who Passed Away. Then She walked in Alive

Jamaican nurse misunderstood her Philadelphia hospital’s memorial paper for late patients and wrote her own name with “Thin Mints.”

MarketBeat

Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out

Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989, during a company news event. Stein said myeloproliferative neoplasms remain “front and center” f

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.